The invention relates to the technical field of microbiological screening and application and specifically provides a novel lactobacillus fermenti strain. The lactobacillus fermenti strain has a collection number of CCTCC NO: M2016430. The strain has obvious inhibitory effects on Escherichia coli, salmonella and staphylococcus aureus, particularly has the strongest inhibitory effect on helicobacter pylori, and the diameter of an inhibition zone reaches 23mm. The lactobacillus fermenti is high in tolerance to gastric acid and bile salts, and is capable of realizing effective multiplication in a gastric acid environment. The lactobacillus fermenti has a cholesterol removal rate of 93.2%, and can maintain the survival rate of 98.5% in 1.2mmol/L H2O2; the fermented supernatant fluid and cell-free extract of the lactobacillus fermenti respectively have the hydroxyl radical scavenging rate of 95.1% and 90.4%. The lactobacillus fermenti can be widely applied to preparation of the lactic acid bacterium drink, is capable of obviously increasing the quantity of intestinal available bacteria, improving the gastrointestinal tract health and improving the immunity of the organism, and has a wide application prospect.